Q4 2019 13F Holders as of 31 Dec 2019
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
57,431,641
-
Share change
-
-1,492,902
-
Total reported value
-
$1,265,206,552
-
Put/Call ratio
-
121%
-
Price per share
-
$22.03
-
Number of holders
-
166
-
Value change
-
+$6,643,926
-
Number of buys
-
106
-
Number of sells
-
49
Institutional Holders of DICERNA PHARMACEUTICALS INC - COM (DRNA) as of Q4 2019
As of 31 Dec 2019,
DICERNA PHARMACEUTICALS INC - COM (DRNA) was held by
166 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
57,431,641 shares.
The largest 10 holders included
RTW INVESTMENTS, LP, BlackRock Inc., Bain Capital Life Sciences Investors, LLC, EcoR1 Capital, LLC, PRICE T ROWE ASSOCIATES INC /MD/, VANGUARD GROUP INC, UBS Group AG, CITADEL ADVISORS LLC, BRIDGER MANAGEMENT, LLC, and EAGLE ASSET MANAGEMENT INC.
This page lists
166
institutional shareholders reporting positions in this security
for the Q4 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.